Faron Pharmaceuticals Oy (LON:FARN - Get Free Report) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 218.04 ($2.94) and traded as high as GBX 220 ($2.97). Faron Pharmaceuticals Oy shares last traded at GBX 214 ($2.89), with a volume of 13,867 shares changing hands.
Faron Pharmaceuticals Oy Trading Down 5.8%
The company has a market cap of £271.93 million, a PE ratio of -5.42 and a beta of 0.36. The company's 50 day simple moving average is GBX 218.43 and its two-hundred day simple moving average is GBX 201.04. The company has a debt-to-equity ratio of 922.55, a current ratio of 1.45 and a quick ratio of 1.09.
Insider Activity at Faron Pharmaceuticals Oy
In other news, insider Markku Jalkanen sold 600,000 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of GBX 310 ($4.18), for a total transaction of £1,860,000 ($2,508,428.86). Corporate insiders own 31.82% of the company's stock.
Faron Pharmaceuticals Oy Company Profile
(
Get Free Report)
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Recommended Stories
Before you consider Faron Pharmaceuticals Oy, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Faron Pharmaceuticals Oy wasn't on the list.
While Faron Pharmaceuticals Oy currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
